2-Carbomethoxy-4-(3,4-dichlorphenyl)-4-cyano-cyclohexanon | 65619-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Carbomethoxy-4-(3,4-dichlorphenyl)-4-cyano-cyclohexanon
• 英文别名: Methyl 5-cyano-5-(3,4-dichlorophenyl)-2-oxocyclohexanecarboxylate；methyl 5-cyano-5-(3,4-dichlorophenyl)-2-oxocyclohexane-1-carboxylate
• CAS: 65619-26-3
• 化学式: C₁₅H₁₃Cl₂NO₃
• 分子量: 326.179
• InChiKey: FIGLLQPCNXNSHQ-UHFFFAOYSA-N

物化性质

• 沸点：
  484.0±45.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  67.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Carbomethoxy-4-(3,4-dichlorphenyl)-4-cyano-cyclohexanon 在 sodium hydroxide 、 lithium aluminium tetrahydride 、 硫酸 、 叠氮磷酸二苯酯 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 乙二醇 、 溶剂黄146 、 苯 为溶剂， 反应 54.0h， 生成 8-(3,4-dichlorophenyl)-N-methyl-1,4-dioxaspiro[4.5]decan-8-amine
  参考文献：
  名称：

  4-Amino-4-arylcyclohexanones and their derivatives, a novel class of analgesics. 1. Modification of the aryl ring

  摘要：

  Investigation of central nervous system activity of phenylcyclohexylamines was continued by preparation of "reversed" analogues. Following the unexpected finding of analgesic activity with 1-(dimethylamino)-1-phenylcyclohexylamine, the SAR of the series was investigated. Synthesis starts by double Michael reaction of acrylate on arylacetonitriles. Following cyclization, decarboxylation, ketalization, and saponification, the geminally substituted acid is rearranged to the isocyanate by means of (C6H5O)2PON3. Isocyanates were then converted to the title compounds. Analgesic activity is very sensitive to the nature and position of the substitutent on the aromatic ring. The most potent compounds in this series (p-CH3, p-Br) showed 50% the potency of morphine. Deletion of the ring oxygen abolishes activity.

  DOI：

  10.1021/jm00178a014
• 作为产物：
  描述：

  3,4-二氯苯乙腈 在 potassium tert-butylate 、 四甲基氢氧化铵 作用下， 生成 2-Carbomethoxy-4-(3,4-dichlorphenyl)-4-cyano-cyclohexanon
  参考文献：
  名称：

  DE2723937

  摘要：

  公开号：

文献信息

• Cycloalkylamines as monoamine reuptake inhibitors
  申请人：Shao Liming

  公开号：US20070203111A1

  公开（公告）日：2007-08-30

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己胺衍生物及其在中枢神经系统（CNS）疾病的治疗和/或预防中的应用，例如抑郁症、焦虑症、精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及包含本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺、5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法和调节一个或多个单胺转运体的方法。
• CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Shao Liming

  公开号：US20100190861A1

  公开（公告）日：2010-07-29

  The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

  本发明涉及新型环己基胺衍生物及其在治疗和/或预防中枢神经系统（CNS）疾病方面的应用，例如抑郁症，焦虑症，精神分裂症和睡眠障碍，以及它们的合成方法。本发明还涉及含有本发明化合物的制药组合物，以及抑制内源性单胺，如多巴胺，5-羟色胺和去甲肾上腺素从突触间隙中再摄取的方法，以及调节一个或多个单胺转运体的方法。
• Potent bradykinin B1 receptor antagonists: 4-Substituted phenyl cyclohexanes
  作者：Dai-Shi Su、John L. Lim、M. Kristine Markowitz、Bang-Lin Wan、Kathy L. Murphy、Duane R. Reiss、C. Meacham Harrell、Stacy S. O’Malley、Rick W. Ransom、Raymond S.L. Chang、Douglas J. Pettibone、Cuyue Tang、Thomayant Prueksaritanont、Roger M. Freidinger、Mark G. Bock

  DOI：10.1016/j.bmcl.2007.03.059

  日期：2007.6

  Selective bradykinin (BK) B-1 receptor antagonists have been shown to be antinociceptive in animal models and could be novel therapeutic agents for the treatment of pain and inflammation. Elucidation of the structure-activity relationships of the biphenyl moiety of the lead compound 1 provided a potent new structural class of BK B-1 receptor antagonists. (C) 2007 Elsevier Ltd. All rights reserved.
• LEDNICER D.; VOIGTLANDER P. F.; EMMERT D. E., J. MED. CHEM., 1980, 23, NO 4, 424-430
  作者：LEDNICER D.、 VOIGTLANDER P. F.、 EMMERT D. E.

  DOI：——

  日期：——
• US4065573A
  申请人：——

  公开号：US4065573A

  公开（公告）日：1977-12-27